Dianthus Therapeutics Financials
| DNTH Stock | 27.38 0.14 0.51% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 19.35 | 18.425 |
|
|
Investors should never underestimate Dianthus Therapeutics' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Dianthus Therapeutics' cash flow, debt, and profitability to make informed and accurate decisions about investing in Dianthus Therapeutics.
Net Income |
|
Dianthus | Select Account or Indicator |
Understanding current and past Dianthus Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Dianthus Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Dianthus Therapeutics' assets may result in an increase in income on the income statement.
Dianthus Therapeutics Stock Summary
Dianthus Therapeutics competes with Willamette Valley, Vector, Universal, Black Mammoth, and Summit Materials. Dianthus Therapeutics is entity of United States. It is traded as Stock on NASDAQ exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| CUSIP | 55910K108 252828108 |
| Location | Massachusetts; U.S.A |
| Business Address | 7 Times Square, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | dianthustx.com |
| Phone | 929 999 4055 |
Dianthus Therapeutics Key Financial Ratios
Dianthus Therapeutics' financial ratios allow both analysts and investors to convert raw data from Dianthus Therapeutics' financial statements into concise, actionable information that can be used to evaluate the performance of Dianthus Therapeutics over time and compare it to other companies across industries.| Return On Equity | -0.27 | ||||
| Operating Margin | (11.92) % | ||||
| Price To Sales | 194.17 X | ||||
| Revenue | 2.83 M | ||||
| Gross Profit | 6.42 M |
Dianthus Therapeutics Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 161.5M | 161.6M | 9.5M | 83.1M | 179.4M | 112.5M | |
| Other Current Liab | 11.3M | 7.7M | 4.0M | 6.6M | 6.5M | 6.5M | |
| Net Debt | (65.1M) | (58.2M) | (7.6M) | (14.6M) | (131.7M) | (125.2M) | |
| Retained Earnings | (179.5M) | (254.4M) | (17.4M) | (45.9M) | (89.4M) | (93.9M) | |
| Accounts Payable | 2.8M | 3.8M | 1.4M | 1.2M | 2.6M | 2.3M | |
| Cash | 65.1M | 58.2M | 7.6M | 15.4M | 132.3M | 138.9M | |
| Other Current Assets | 4.1M | 2.7M | 10K | 53K | 3.3M | 1.9M | |
| Total Liab | 20.3M | 17.7M | 26.7M | 127.5M | 10.5M | 10.0M | |
| Total Current Assets | 149.8M | 151.5M | 9.4M | 82.0M | 177.5M | 107.1M | |
| Common Stock | 39K | 49K | 59K | 61K | 15K | 14.3K |
Dianthus Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Dianthus Therapeutics's current stock value. Our valuation model uses many indicators to compare Dianthus Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Dianthus Therapeutics competition to find correlations between indicators driving Dianthus Therapeutics's intrinsic value. More Info.Dianthus Therapeutics is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers . As of now, Dianthus Therapeutics' Return On Equity is increasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Dianthus Therapeutics' earnings, one of the primary drivers of an investment's value.Dianthus Therapeutics Systematic Risk
Dianthus Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Dianthus Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was sixteen with a total number of output elements of fourty-five. The Beta measures systematic risk based on how returns on Dianthus Therapeutics correlated with the market. If Beta is less than 0 Dianthus Therapeutics generally moves in the opposite direction as compared to the market. If Dianthus Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Dianthus Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Dianthus Therapeutics is generally in the same direction as the market. If Beta > 1 Dianthus Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Dianthus Therapeutics Thematic Clasifications
Dianthus Therapeutics is part of Pharmaceutical Products investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
| Pharmaceutical Products | View |
Today, most investors in Dianthus Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Dianthus Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Dianthus Therapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Dianthus Therapeutics October 1, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Dianthus Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Dianthus Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Dianthus Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Dianthus Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Dianthus Therapeutics's daily price indicators and compare them against related drivers.
| Downside Deviation | 4.22 | |||
| Information Ratio | 0.0255 | |||
| Maximum Drawdown | 20.71 | |||
| Value At Risk | (6.54) | |||
| Potential Upside | 7.67 |
Complementary Tools for Dianthus Stock analysis
When running Dianthus Therapeutics' price analysis, check to measure Dianthus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dianthus Therapeutics is operating at the current time. Most of Dianthus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dianthus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dianthus Therapeutics' price. Additionally, you may evaluate how the addition of Dianthus Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |